3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Dermatologic
2
Plasma cell
1
Other hematologic neoplasm
1
Gynecologic
1
CNS
1
Conditions
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Basal Cell Nevus Syndrome
1
Interventions
Paclitaxel
69
Carboplatin
66
Cisplatin
36
pembrolizumab
34
Gemcitabine
24
liposomal doxorubicin
23
Cyclophosphamide
23
Topotecan
22
Bevacizumab
20
Taxes
14
Docetaxel
13
niraparib
12
Nivolumab
12
olaparib
10
fludarabine
10
Doxorubicin
9
Surveys and Questionnaires
8
Radiotherapy
8
Oxaliplatin
8
aldesleukin
7
Filgrastim
7
rucaparib
6
oregovomab
6
fludarabine phosphate
6
durvalumab
6
avelumab
6
Interleukin-2
6
Hyperthermic Intraperitoneal Chemotherapy
6
Fluorodeoxyglucose F18
6
Cytoreduction Surgical Procedures
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
sonidegib
×
Gynecologic
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts